| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| May 7, 2026 | ±4.4% | -0.0% | over-priced |
| November 5, 2025 | ±3.9% | -5.7% | under-priced |
| August 6, 2025 | ±3.4% | -10.3% | under-priced |
| May 7, 2025 | ±4.3% | +18.7% | under-priced |
| November 6, 2024 | ±3.3% | +13.5% | under-priced |
| August 7, 2024 | ±5.3% | -12.6% | under-priced |
| May 9, 2024 | ±2.3% | -2.2% | over-priced |
| November 8, 2023 | ±3.5% | -3.7% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $-0.30 | $996M | $-15M |
| Q4 FY2025 | $-5.56 | $994M | $-276M |
| Q3 FY2025 | $1.10 | $1.0B | $56M |
| Q2 FY2025 | $1.06 | $1.0B | $53M |
Charles River Laboratories International, Inc. (CRL) reports in 99 days, with the next report estimated for September 20, 2026. Across the last 8 reports, options priced an average ±3.8% earnings move while the stock actually moved 8.3% on average — the market has tended to under-price CRL's earnings risk. Fundamentals into the print: EPS down 160.0% year-over-year, revenue up 1.2%. QuantLogix's live 5-factor engine currently reads CRL as a buy at 52/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →